COPD Diagnosis and Management Review

The $\text{FEV}_1/\text{FVC}$ Ratio

The definitive diagnostic marker for COPD is the post-bronchodilator $\text{FEV}_1/\text{FVC}$ ratio. This ratio represents the proportion of the total air capacity that a patient can forcefully exhale within the first second of a breath.

A diagnosis of COPD is confirmed when: $\frac{\text{FEV}_1}{\text{FVC}} < 0.7$

Exam Tip: If a question asks for the specific numerical value that confirms a COPD diagnosis via spirometry, remember the threshold is strictly less than 0.7.

Assessing Symptom Severity

Once a diagnosis is established, the clinician must determine how much the disease is impacting the patient's daily life. This is not done through lung volumes alone, but through validated symptom scoring tools.

mMRC (modified Medical Research Council dyspnea scale)

The mMRC scale is used specifically to grade the level of dyspnea (breathlessness) a patient experiences during physical activity. It helps clinicians understand how much a patient's breathing limits their mobility.

CAT (COPD Assessment Test)

While the mMRC focuses on breathlessness, the CAT is a broader questionnaire. It evaluates the overall impact of COPD symptoms—such as cough, phlegm, and chest tightness—on the patient's daily well-being and general lifestyle.

Pharmacological Management and Targeted Therapy

Management of COPD typically involves bronchodilators to relieve airflow obstruction. However, modern guidelines emphasize "phenotyping"—treating the specific type of inflammation present in the patient.

The Role of Inhaled Corticosteroids (ICS)

Inhaled corticosteroids are not used for all COPD patients. Their use is specifically indicated when a patient exhibits a certain inflammatory profile.

Using Eosinophil Counts to Guide Therapy

The most critical clinical marker for determining if a patient should receive ICS therapy is the blood eosinophil count. Eosinophils are a type of white blood cell associated with specific inflammatory pathways.

• High Eosinophil Count ($>300$ cells/$\mu$L): Suggests the patient has an inflammatory phenotype that is likely to respond well to corticosteroid treatment.

Clinical Pearl: When deciding whether to add an ICS to a patient's regimen, always check the eosinophil count. A count above 300 cells/$\mu$L is a strong indicator for ICS usage.

---

Summary Table for Quick Review